Can ubrogepant and galcanezumab be used concurrently in patients with chronic migraine, and what are the potential benefits and risks?

Concurrent use of ubrogepant and galcanezumab in chronic migraine is supported by limited or indirect evidence primarily focusing on pharmacokinetics and safety, indicating potential for combined use without major adverse interactions, but direct clinical efficacy studies are lacking.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-02
DOI
https://doi.org/10.5281/zenodo.23879724
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Can ubrogepant and galcanezumab be used concurrently in patients with chronic migraine, and what are the potential benefits and risks?

Tripdatabase
1 links
Zenodo (CERN European Organization for Nuclear Research)
Migraine and Headache Studies
article

Can ubrogepant and galcanezumab be used concurrently in patients with chronic migraine, and what are the potential benefits and risks?

Tripdatabase
article en

Abstract

Concurrent use of ubrogepant and galcanezumab in chronic migraine is supported by limited or indirect evidence primarily focusing on pharmacokinetics and safety, indicating potential for combined use without major adverse interactions, but direct clinical efficacy studies are lacking.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 14%
Migraine and Headache Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Can ubrogepant and galcanezumab be used concurrently in patients with chronic migraine, and what are the potential benefits and risks? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS